Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to previous ... Read more
The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of advanced ... Read more
Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to a Phase 1 clinical trial. The treatment — jointly ... Read more
The U.S. Food and Drug Administration has expanded Alimta‘s (pemetrexed) label to include a combination with Keytruda (pembrolizumab) and platinum chemotherapy for the initial treatment of certain metastatic non-small cell lung cancer (NSCLC) patients. ... Read more
The European Commission has approved a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for the initial treatment of advanced renal cell carcinoma patients with intermediate and poor risk, making ... Read more
A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients and doubled survival rates over patients treated with Vidaza ... Read more
Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings from ... Read more
A combination of Opdivo (nivoumab) and Yervoy (ipilimumab) significantly delayed the need for a subsequent treatment in patients with advanced or metastatic renal cell carcinoma who had not previously been ... Read more
The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD outside ... Read more